Liver cirrhosis and decompensation still on the rise among people with hepatitis C
Is DAA treatment for hepatitis C reducing the need for liver transplants?
Sofosbuvir-based therapy achieves excellent SVR12 rates among people who inject drugs in Ukraine
Hepatitis C virus infection is rising among gay and bisexual men in San Diego
Sofosbuvir/ledipasvir is effective for people with HIV/HCV co-infection in real-world clinical practice
Grazoprevir triple regimen demonstrates high cure rates, even for hard-to-treat people
People with HIV/HCV co-infection see good cure rates in real-world practice in Madrid
8-week triple DAA combo cures most people with genotype 1-6 hepatitis C
Birth cohort screening and linkage to care for HCV treatment still weak in United States
AbbVie pangenotypic combination cures 98% or above across genotypes
AbbVie pangenotypic combination cures almost all hard-to-treat people with HCV genotype 3
US Veterans Affairs and Australia show potential for rapid elimination of hepatitis C
Tenofovir alafenamide approved for hepatitis B, works well with less effect on bones
Grazoprevir/elbasvir + sofosbuvir highly effective for hard-to-treat genotype 3 hepatitis C patients
